Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We have 16 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.4 billion (IQVIA, April 2019).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"We are forging the path to profitable growth and will continue to make the tough decisions needed to grow this business responsibly."

Damian Finio

Recent News

Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

Scheduled to Reconvene on November 11 , 2020 Company Urgently Encourages Stockholders to Vote BUENA, N.J. , Oct. 22, 202...

Learn More

Teligent Announces Completion of Series D Convertible Note Exchange

BUENA, N.J. , Sept. 23, 2020 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jer...

Learn More

Teligent, Inc. Announces Second Quarter 2020 Results

BUENA, N.J. , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...

Learn More

Investor Overview

There are no items to display.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.